- Home
- WLDN vs HRMY Comparison
WLDN vs HRMY Comparison
Compare WLDN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLDN
- HRMY
- Stock Information
- Founded
- WLDN 1964
- HRMY 2017
- Country
- WLDN United States
- HRMY United States
- Employees
- WLDN N/A
- HRMY N/A
- Industry
- WLDN Military/Government/Technical
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- WLDN Consumer Discretionary
- HRMY Health Care
- Exchange
- WLDN Nasdaq
- HRMY Nasdaq
- Market Cap
- WLDN 1.6B
- HRMY 1.5B
- IPO Year
- WLDN 2006
- HRMY 2020
- Fundamental
- Price
- WLDN $96.21
- HRMY $34.55
- Analyst Decision
- WLDN Strong Buy
- HRMY Strong Buy
- Analyst Count
- WLDN 3
- HRMY 9
- Target Price
- WLDN $114.33
- HRMY $50.44
- AVG Volume (30 Days)
- WLDN 263.8K
- HRMY 902.8K
- Earning Date
- WLDN 11-06-2025
- HRMY 11-04-2025
- Dividend Yield
- WLDN N/A
- HRMY N/A
- EPS Growth
- WLDN 71.17
- HRMY 50.44
- EPS
- WLDN 2.79
- HRMY 3.17
- Revenue
- WLDN $651,926,000.00
- HRMY $825,944,000.00
- Revenue This Year
- WLDN N/A
- HRMY $20.68
- Revenue Next Year
- WLDN $9.00
- HRMY $15.93
- P/E Ratio
- WLDN $34.85
- HRMY $10.83
- Revenue Growth
- WLDN 12.90
- HRMY 21.13
- 52 Week Low
- WLDN $30.43
- HRMY $25.52
- 52 Week High
- WLDN $121.00
- HRMY $40.93
- Technical
- Relative Strength Index (RSI)
- WLDN 53.01
- HRMY 70.83
- Support Level
- WLDN $92.46
- HRMY $32.77
- Resistance Level
- WLDN $100.97
- HRMY $34.80
- Average True Range (ATR)
- WLDN 5.68
- HRMY 1.36
- MACD
- WLDN 0.45
- HRMY 0.23
- Stochastic Oscillator
- WLDN 74.40
- HRMY 94.01
About WLDN Willdan Group Inc.
Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.